TSE:TRIL

Trillium Therapeutics - TRIL Stock Forecast, Price & News

Add

Compare

Today's Range: N/A
50-Day Range: C$23.33
▼
C$23.33
52-Week Range: N/A

Volume: 60,423 shs
Average Volume: 166,586 shs
Market Capitalization: C$2.45 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About Trillium Therapeutics (TSE:TRIL) Stock

Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. Its include TTI-622, a SIRPa-IgG4 Fc fusion protein that is designed to enhance macrophage-mediated phagocytosis and anti-tumor activity by blocking the CD47, which is in Phase 1 clinical trials; and TTI-621, a SIRPa-IgG1 Fc fusion protein, which is in Phase 1 clinical trials and generates a signal blocking the CD47 for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was incorporated in 2004 is based in Mississauga, Canada.

Receive TRIL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Trillium Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TRIL Stock News Headlines

March 13, 2023 | finance.yahoo.com

Ratio Therapeutics Appoints Dr. Noel Monks as Head of Biology

March 13, 2023 | reuters.com

Factbox: Pfizer snaps up Seagen for $43 bln as drugmaker extends buying spree

March 23, 2023 | Health Sector Insight (Ad)

Penny Stock Shows Big Potential

The $4.37 trillion wellness market and the little-known penny stock to get on radar now.

February 24, 2023 | benzinga.com

Allogene Therapeutics Stock (NASDAQ:ALLO), Quotes and News Summary

February 23, 2023 | finance.yahoo.com

Tvardi Therapeutics Announces First Patients Dosed in Phase 2 Trial of TTI-101 in Metastatic Breast Cancer

February 6, 2023 | markets.businessinsider.com

Viridian Therapeutics Names Scott Myers CEO, Succeeding Jonathan Violin

October 26, 2022 | finance.yahoo.com

Alex Therapeutics presents results from digital therapeutic pilot study showing nearly 50% reduction in anxiety

August 5, 2022 | finance.yahoo.com

Pfizer in advanced talks to buy Global Blood Therapeutics for $5 billion - WSJ

March 23, 2023 | Health Sector Insight (Ad)

Penny Stock Shows Big Potential

The $4.37 trillion wellness market and the little-known penny stock to get on radar now.

July 29, 2022 | ca.finance.yahoo.com

Leukemia Therapeutics Global Market Report 2022

July 18, 2022 | thestreet.com

Trillium Therapeutics Inc. News

June 10, 2022 | finance.yahoo.com

Ratio Therapeutics Launches to Discover and Drive Early Clinical Development of Best-in-Class Targeted Radiopharmaceuticals for Treatment of Cancers

May 10, 2022 | finanznachrichten.de

Bloom Burton & Co. Inc.: Three Finalists Announced for the 2022 Bloom Burton Award

January 26, 2022 | finance.yahoo.com

GenScript ProBio Initiates a CDMO Contract For Next-Generation CD47 Antibody with InnoBation Bio

December 16, 2021 | au.finance.yahoo.com

CD47 Targeting Global Therapeutics Market 2021-2035, by Target Disease Indication, Type of Molecule Key Players and Key Geographical Regions

October 28, 2021 | finance.yahoo.com

Trillium Therapeutics Receives Final Court Order Approving Arrangement

October 26, 2021 | theglobeandmail.com

Shareholders of cancer-drug developer Trillium Therapeutics approve takeover by Pfizer Inc.

October 26, 2021 | finance.yahoo.com

Trillium Securityholders Approve Acquisition by Pfizer

October 5, 2021 | finance.yahoo.com

Is Trillium Therapeutics Inc. (TSE:TRIL) Popular Amongst Institutions?

September 14, 2021 | markets.businessinsider.com

Here's the Biotech Pfizer Should Consider Acquiring Next

August 26, 2021 | finance.yahoo.com

INVESTIGATION: Halper Sadeh LLP Investigates LMRK, HFC, NLOK, TRIL, LDL; Shareholders are Encouraged to Contact the Firm

August 24, 2021 | finance.yahoo.com

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Trillium Therapeutics Inc. (Nasdaq – TRIL)

August 23, 2021 | businesswire.com

TRILLIUM THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Trillium ...

August 23, 2021 | thestreet.com

Top 5 Stock Gainers for Monday: Pfizer, Trillium, NextGen, Vivos

August 23, 2021 | markets.businessinsider.com

Mid-Morning Market Update: Markets Open Higher; Pfizer To Acquire Trillium Therapeutics

August 23, 2021 | finance.yahoo.com

Pfizer Beefs Up Blood Cancer Pipeline With Trillium Acquisition: See Highlights

August 23, 2021 | finance.yahoo.com

Why Trillium Therapeutics Stock Is Skyrocketing Today

See More Headlines

Receive TRIL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Trillium Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: TSE
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: TSE:TRIL
Previous Symbol: TSE:SSS
CUSIP: N/A
CIK: N/A
Web: www.trilliumtherapeutics.com
Phone: +1-416-5950627
Fax: N/A
Employees: 33
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 0.27
Current Ratio: 12.04
Quick Ratio: 11.54

Sales & Book Value

Annual Sales: C$43,000.00
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: 9.77
Book Value: C$2.17 per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 104,995,000
Free Float: N/A
Market Cap: C$2.45 billion
Optionable: Optionable
Beta: N/A

Key Executives

Dr. Jan Skvarka (Age 54)
Pres, CEO & Director
Comp: $812.5k

Mr. James T. Parsons C.A. (Age 56)
C.P.A., MAcc, CPA-CA, Chief Financial Officer
Comp: $543.38k

Dr. Robert Uger (Age 50)
Chief Scientific Officer
Comp: $595.73k

Dr. Penka Petrova (Age 53)
Chief Devel. Officer
Comp: $553.53k

Dr. Ingmar Bruns M.D. (Age 46)
Ph.D., Chief Medical Officer
Comp: $230k

Benjamin Looker
Gen. Counsel

Dr. Rosemary Harrison (Age 38)
Sr. VP of Corp. Devel. & Strategy

Dr. Michael G. Hill
Head of Calgary Site

Ms. Kathleen Large (Age 61)
Sr. VP - Clinical Operations

Key Competitors

View All Competitors

TRIL Stock - Frequently Asked Questions

What other stocks do shareholders of Trillium Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Trillium Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Canada Goose (GOOS), Moderna (MRNA), Shopify (SHOP), Block (SQ), Teladoc Health (TDOC), Zoom Video Communications (ZM), Advanced Micro Devices (AMD) and Canadian Natural Resources (CNQ).
What is Trillium Therapeutics' stock symbol?: Trillium Therapeutics trades on the Toronto Stock Exchange (TSX) under the ticker symbol "TRIL."

How do I buy shares of Trillium Therapeutics?: Shares of TRIL stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.
How much money does Trillium Therapeutics make?: Trillium Therapeutics (TSE:TRIL) has a market capitalization of C$0.00 and generates C$43,000.00 in revenue each year.
How can I contact Trillium Therapeutics?: Trillium Therapeutics' mailing address is 2488 Dunwin Dr, MISSISSAUGA, ON L5L 1J9, Canada. The official website for the company is www.trilliumtherapeutics.com. The company can be reached via phone at +1-416-5950627.

This page (TSE:TRIL) was last updated on 3/23/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial